Owner Scorecard


← All companies ← EVAX Manual EXK → ← EVMN Pharmaceuticals FBIOP →

EVO, Evotec SE

Pharmaceuticals consumer brand UnprofitableCyclical

Revenue is D&PD (77%) and JEB (23%).

Latest annual: FY2024 20-F · figures as filed, in EUR · 1 ADS = 0.5 ordinary shares
EVO · Evotec SE
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2024
€797M
+2.0% YoY · 12% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue €797M 5-yr avg €690M
Gross margin 14% 5-yr avg 22%
Operating margin −17.9% 5-yr avg −1.0%
ROIC −11% 5-yr avg −6%
Owner-earnings margin −12% 5-yr avg 1%
Free cash flow margin −12% 5-yr avg −8%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
What moves the needle
Gross margin has run about 23% and operating margin about 2.8% through the cycle, a thin spread that turns the result on volume and the cost of what it sells far more than on the price it sets. The margin is cyclical, swinging between −18% and 14% over the years, so the through-cycle figure carries more than any single year — and the balance sheet at the trough more than the peak. Capital spending runs about 19% of sales, well above depreciation, so the return earned on what it sinks into that plant weighs as much as the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −1%, above 15% in 1 of 4 years). Owner earnings, the cash-based check, have been thin too. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 20-F →

D&PD is 77% of revenue, with JEB the other meaningful segment at 23%.

Revenue by reportable segment, FY2024
  • D&PD77%€611M
  • JEB23%€186M
By geographyUnited States56%Switzerland14%United Kingdom12%Rest of the world10%Germany4%France2%

From the segment footnote of the company's own 20-F. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2019–2024

realized figures from each filing · older years to the left
2019’192020’202021’212022’222023’232024’24TTMTTMDec 2024
Income statement
€446M€501M€618M€751M€781M€797M€797MRevenueRevenue
30%25%25%23%22%14%14%Gross marginGross mgn
€63M€49M€41M€21M(€48M)(€143M)(€143M)Operating incomeOp. inc.
14.0%9.7%6.6%2.8%−6.1%−17.9%−17.9%Operating marginOp. mgn
€38M€6M€216M(€176M)(€84M)(€196M)(€176M)Net incomeNet inc.
Cash flow & returns
€42M€45M€127M€206M€36M€18M€18MOperating cash flowOp. cash
€36M€42M€70M€83M€93M€102M€102MDepreciationDeprec.
(€32M)(€4M)(€159M)€298M€27M€113M€92MWorking capital & otherWC & other
€31M€99M€119M€181M€213M€117M€117MCapexCapex
7.0%19.8%19.2%24.1%27.3%14.7%14.7%Capex / revenueCapex/rev
€11M€3M€56M€123M(€57M)(€99M)(€99M)Owner earningsOwner earn.
2.4%0.5%9.1%16.3%−7.2%−12.5%−12.5%Owner earnings marginOE mgn
€11M(€54M)€8M€24M(€177M)(€99M)(€99M)Free cash flowFCF
2.4%−10.9%1.2%3.3%−22.6%−12.5%−12.5%Free cash flow marginFCF mgn
21%4%-5%-17%-11%ROICROIC
8%1%16%-15%-7%-21%-18%Return on equityROE
8%1%16%−15%−7%−21%−18%Retained to equityRetained/eq
Balance sheet
€277M€482M€858M€718M€604M€397M€397MCash & investmentsCash+inv
€79M€132M€172M€98M€116M€116MReceivablesReceiv.
€14M€26M€30M€31M€31M€31MInventoryInvent.
€97M€134M€86M€86MAccounts payablePayables
€93M€158M€104M(€5M)€62M€62MOperating working capitalOper. WC
€659M€1.1B€1.1B€903M€682M€682MCurrent assetsCur. assets
€208M€325M€338M€465M€345M€345MCurrent liabilitiesCur. liab.
3.2×3.4×3.2×1.9×2.0×2.0×Current ratioCurr. ratio
€256M€247M€258M€275M€276M€283M€283MGoodwillGoodwill
€1.5B€2.2B€2.3B€2.3B€1.9B€1.9BTotal assetsAssets
€331M€326M€330M€130M€27M€355MTotal debtDebt
(€151M)(€532M)(€389M)(€474M)(€370M)(€41M)Net debt / (cash)Net debt
8.4×5.7×4.4×1.6×-10.8×Interest coverageInt. cov.
€479M€724M€1.4B€1.2B€1.1B€953M€953MShareholders’ equityEquity
Per share
150M154M166M177M177M177M178MShares out (diluted)Shares
€2.98€3.26€3.71€4.25€4.42€4.50€4.49Revenue / shareRev/sh
€0.25€0.04€1.30€-0.99€-0.47€-1.11€-0.99EPS (diluted)EPS
€0.07€0.02€0.34€0.69€-0.32€-0.56€-0.56Owner earnings / shareOE/sh
€0.07€-0.35€0.05€0.14€-1.00€-0.56€-0.56Free cash flow / shareFCF/sh
€0.21€0.64€0.71€1.03€1.21€0.66€0.66Cap. spending / shareCapex/sh
€3.20€4.71€8.28€6.72€6.33€5.37€5.36Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
5-yr5-yr
Revenue / share+8.6%/yr+8.6%/yr
Capital spending / share+25.9%/yr+25.9%/yr
Book value / share+10.9%/yr+10.9%/yr

The record, charted

FY2019–2024

Each measure over its full record; the current point and the worst year marked.

Share count
177Mpeak FY2024
ROIC
−17%low FY2024
Gross margin
14%low FY2024

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

(€99M)owner earningsvs.(€196M)net incomelow FY2024

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2019FY2024

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2024 the business turned a €196M loss into (€99M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2024FY2023FY2022FY2021FY2020
Reported net income(€196M)(€84M)(€176M)€216M€6M
Depreciation & amortizationnon-cash charge added back+€102M+€93M+€83M+€70M+€42M
Working capital & othertiming of cash in and out, other non-cash items+€113M+€27M+€298M−€159M−€4M
Cash from operations€18M€36M€206M€127M€45M
Maintenance capital expenditurethe spending needed just to hold position and volume−€117M−€93M−€83M−€70M−€42M
Owner earnings(€99M)(€57M)€123M€56M€3M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−€120M−€98M−€49M−€57M
Free cash flow(€99M)(€177M)€24M€8M(€54M)
Owner-earnings marginowner earnings ÷ revenue-12%-7%16%9%1%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2024 20-F · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income (€143M) ÷ interest expense €13M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash €306M + ST investments €90M − debt €355M
    What this means

    Cash and short-term investments exceed every dollar of debt by €41M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Tight
    DSO 53 + DIO 17 − DPO 46 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Below average through the cycle
    4-yr median, range -17%–21%; -11% latest = NOPAT (€113M) ÷ invested capital €1.0B
    Industry peers: median 6%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 4 years (it ran -11% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Thin through the cycle
    6-yr median margin, range -12%–16%; latest (€99M) = operating cash €18M − maintenance capex €117M
    Industry peers: median 16%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -12% of revenue this year, a 1% median across 6 years.

  • Loss, but cash-generative
    Net income (€176M) · cash from operations €18M
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 1.16×
    Maintaining
    Capex €117M ÷ depreciation €102M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 0 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €797M
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Near
    Current ratio ≥ 2× · 1.98×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Near
    Debt ≤ working capital · €355M vs €337M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (6-yr record) · 3 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth Miss
    Earnings +33% over the record · −275%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €-0.85/share (latest year €-0.99), the averaged base the calculator's gate runs on, and book value is €5.36/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2019–2024

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 3 of 6
    What this means

    Lost money in 3 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 5 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin 10% → −7% (3-yr avg ends)

    In the filing’s words Input costs rose and the filing says it could not fully pass them on — which is where this margin compressed.

    What this means

    Through the cycle the operating margin slipped — about 10% early to −7% lately, median 3% — competition or costs are biting in.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2024 · −17.9% op. margin
    What this means

    Operations went underwater in 2024, understand why before trusting the good years.

  • Share count +3.4%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Framed as a capability

The filing positions AI as something the company uses, not something it fears.

“As a result, pharmaceutical companies of all sizes have been and continue to be under pressure to re-evaluate and adjust their business strategies, in particular by accessing innovative technologies, such as AI and ML, and pursuing innovative treatment modalities, such as persona…”

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2024

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€682M
  • Cash & short-term investments€397M
  • Receivables€116M
  • Inventory€31M
  • Other current assets€138M
Current liabilities€345M
  • Debt due within a year€27M
  • Accounts payable€86M
  • Other current liabilities€232M
Current ratio1.98×all current assets ÷ what's due · Graham looked for 2×
Quick ratio1.89×stricter: inventory excluded
Cash ratio1.15×strictest: cash alone against what's due
Working capital€337Mthe cushion left after near-term bills
Debt due this year vs. cash€27M due · €397M cash covered by cash on hand, no refinancing forced · both figures from the Dec 31, 2024 balance sheet
Deeper floors
Tangible book value€643Mequity stripped of goodwill & intangibles
Debt incl. operating leases€507M€152M of it operating leases
Deferred revenue€107Mcustomer cash collected before delivery; operating float

From the company's latest filing.

How the cash was used, 2019–2024

Over the record, the business generated €474M of operating cash; how management split it reads as a reinvestor, most operating cash is plowed back into the business.

  • Reinvested€761M · 161%
  • Source of funding−€287M

    Reinvestment and shareholder returns ran €287M beyond the operating cash the business generated, so the gap was financed off the balance sheet.

  • Net change in share count18.6%

    The diluted count rose from 150M to 178M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record

    No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
ANIPANI Pharmaceuticals Inc.$883M62%8.8%4%17%
ARWRArrowhead Pharmaceuticals$829M-106.8%-51%-77%
EVOEvotec SE€797M24%4.7%-1%1%
COLLCollegium Pharmaceutical Inc.$781M56%6.8%44%31%
CORTCorcept Therapeutics Incorporated$761M98%30.6%25%34%
EBSEmergent BioSolutions Inc.$743M58%12.5%6%8%
PCRXPacira BioSciences$726M73%3.7%2%16%
AMPHAmphastar Pharmaceuticals Inc.$720M43%11.0%9%15%
Group median58%7.8%5%15%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American Depositary Shares, each representing one-half of one ordinary”; Evotec SE reports in EUR, so every figure in this tool is stated per ADS and translated at EUR 1 = $1.145 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in EUR.

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Evotec SE has delivered.

Evotec SE’s latest year shows negative owner earnings, a cyclical trough. So the tool opens on the through-cycle base, the cash it would earn at rest; clear the toggle below to read the latest year exactly as reported.

$

Through the cycle, Evotec SE earns about $13M on its 1.5% median owner-earnings margin. This year’s −12.5% margin runs below that; the reported figure may understate a lean year. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth, delivered
Owner-earnings yield
P/E (3-yr earnings ’22–’24)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings ($114M) on 356M shares outstanding, per the 20-F cover, as of 2025-12-31; net cash $47M. The base opens on the through-cycle figure (the latest year sits off the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Evotec SE (EVO), the owner's record," https://ownerscorecard.com/c/EVO, data as of 2026-07-09.

Manual order: ← EVAX its page in the Manual EXK →

Industry order: ← EVMN the Pharmaceuticals chapter FBIOP →